# Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring a 164.71% Upside Potential in Biotechnology

- Link: https://www.directorstalkinterviews.com/viking-therapeutics-inc-vktx-stock-analysis-exploring-a-164-71-upside-potential-in-biotechnology/4121210796
- Published: 2025-08-05T10:22:24+01:00
- Author: Madison Wilson

Viking Therapeutics, Inc. (NASDAQ: VKTX) has garnered significant attention in the
biotechnology sector with its innovative approach to treating metabolic and endocrine
disorders. Headquartered in San Diego, California, Viking Therapeutics is a clinical-
stage biopharmaceutical company that focuses on developing novel therapies, with
a promising pipeline that has captured the interest of investors and analysts alike.

With a market cap of $3.82 billion, Viking Therapeutics stands as a notable player
in the healthcare sector. The company is currently trading at $33.98, having experienced
a minor price change of 0.04% recently. Over the past 52 weeks, the stock has seen
a range between $19.98 and $78.03, reflecting its potential for volatility and opportunity.

One of the standout metrics for Viking Therapeutics is its potential upside of 164.71%,
based on the average target price of $89.95 set by analysts. This figure is particularly
compelling, as it suggests substantial growth potential for the stock. Analysts 
have shown strong confidence in Viking Therapeutics, with 17 buy ratings and only
2 hold ratings, and no sell ratings, indicating a positive outlook from the investment
community.

Viking Therapeutics is currently in the clinical trial phase with several promising
candidates. The lead drug, VK2809, is in Phase IIb trials targeting non-alcoholic
steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Additionally,
the company is advancing other candidates like VK5211, VK0612, VK2735, and VK0214,
addressing a range of conditions from hip fracture recovery to type 2 diabetes and
rare genetic disorders.

However, investors should note the inherent risks associated with clinical-stage
companies. Viking Therapeutics currently reports no revenue growth, a negative EPS
of -1.60, and a return on equity of -19.99%. The company’s free cash flow is also
negative at -$102.1 million, highlighting the typical cash burn associated with 
developing new therapies. The forward P/E ratio of -11.49 indicates that the company
is not yet profitable, which is common in this stage of development.

From a technical perspective, Viking Therapeutics shows some interesting signals.
The stock’s RSI (14) stands at 71.41, suggesting that it may be approaching overbought
territory, which could precede a price correction. Meanwhile, the MACD of 1.31 and
a signal line of 1.35 indicate a bullish trend. The 50-day moving average is $29.20,
below the current price, while the 200-day moving average is slightly above at $
36.46, demonstrating recent strength in the stock.

Despite the current lack of profitability, the potential for significant returns
is what makes Viking Therapeutics an intriguing option for investors willing to 
take on the risk associated with biopharmaceutical ventures. The company’s innovative
pipeline and high analyst ratings underscore a strong belief in its future prospects
within a competitive market. Investors looking to capitalize on the growth potential
in the biotech sector may find Viking Therapeutics an attractive addition to their
portfolios, provided they are prepared for the volatility and risks that accompany
such investments.

Share on: